Inhibitor development in haemophilia according to concentrate

Kathelijn Fischer; Riita Lassila; Flora Peyvandi; Gabriele Calizzani; Alex Gatt; Thierry Lambert; Jerzy Windyga; Alfonso Iorio; Estelle Gilman; Michael Makris

doi:10.1160/TH14-10-0826

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2015; 113(05): 968-975
DOI: 10.1160/TH14-10-0826

Coagulation and Fibrinolysis

Schattauer GmbH

Inhibitor development in haemophilia according to concentrate

Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project

Kathelijn Fischer

¹Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, The Netherlands

²Van Creveldkliniek, University Medical Centre Utrecht, The Netherlands

,

Riita Lassila

³Department of Hematology, Unit of Coagulation Disorders, Helsinki University Central Hospital, Finland

,

Flora Peyvandi

⁴Angelo Bianchi Bonomi, Hemophilia and Thrombosis centre, IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

⁵Department of pathophysiology and Transplantation, University of Milan, Milan, Italy

,

Gabriele Calizzani

⁶European Haemophilia consortium and Italian National Blood Centre, Rome, Italy

,

Alex Gatt

⁷Mater Dei Hospital, Tal-QRoqq, Msida, Malta;

,

Thierry Lambert

⁸Hopital Bicetre, Paris, France

,

Jerzy Windyga

⁹Institute for Hematology and Transfusion Medicine, Warsaw, Poland

,

Alfonso Iorio

¹⁰Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

¹¹Department of Medicine, McMaster University, Hamilton, Ontario, Canada

,

Estelle Gilman

¹²Department of Cardiovascular Science, University of Sheffield, Sheffield, UK;

,

Michael Makris

¹³Sheffield Haemophilia and Thrombosis Centre, University of Sheffield, Sheffield, UK

› Institutsangaben

Abstract

Summary

Inhibitor development represents the most serious side effect of haemophilia treatment. Any difference in risk of inhibitor formation depending on the product used might be of clinical relevance. It was this study’s objective to assess inhibitor development according to clotting factor concentrate in severe haemophilia A and B. The European Haemophilia Safety Surveillance (EUHASS) was set up as a study monitoring adverse events overall and according to concentrate. Since October 2008, inhibitors were reported at least quarterly. Number of treated patients was reported annually, specifying the number of patients completing 50 exposure days (Previously Untreated Patients, PUPs) without inhibitor development. Cumulative incidence, incidence rates and 95 % confidence intervals (CI) were calculated. Data from October 1, 2008 to December 31, 2012 were analysed for 68 centres that validated their data. Inhibitors developed in 108/417 (26 %; CI 22–30 %) PUPs with severe haemophilia A and 5/72 (7 %; CI 2–16%) PUPs with severe haemophilia B. For Previously Treated Patients (PTPs), 26 inhibitors developed in 17,667 treatment years [0.15/100 treatment years; CI 0.10–0.22) for severe haemophilia A and 1/2836 (0.04/100; (CI 0.00–0.20) for severe haemophilia B. Differences between plasma-derived and recombinant concentrates, or among the different recombinant FVIII concentrates were investigated. In conclusion, while confirming the expected rates of inhibitors in PUPs and PTPs, no class or brand related differences were observed.

Keywords

Adverse Drug Reaction Reporting Systems - antibodies - neutralising - factor VIII - haemophilia A - haemophilia B

Volltext

Referenzen

References
1 Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-1779.
2 Pool JG, Shannon AE. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system. N Engl J Med 1965; 273: 1443-1447.
3 Rabiner SF, Telfer MC. Home transfusion for patients with hemophilia A. N Engl J Med 1970; 283: 1011-1015.
4 Nilsson IM, Blomback M, Ahlberg A. Our experience in Sweden with prophylaxis on haemophilia. Bibl Haematol 1970; 34: 111-124.
5 Gouw SC, Van der Bom JG, Van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-4654.
6 Gouw SC, Van den Berg HM, Fischer K. et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013; 121: 4046-4055.
7 Darby SC, Keeling DM, Spooner RJ. et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. J Thromb Haemost 2004; 02: 1047-1054.
8 Xi M, Makris M, Marcucci M. et al. Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. J Thromb Haemost 2013; 11: 1655-1662.
9 Goudemand J, Laurian Y, Calvez T. Risk of inhibitors in haemophilia and the type of factor replacement. Curr Opin Hematol 2006; 13: 316-322.
10 Iorio A, Halimeh S, Holzhauer S. et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 08: 1256-1265.
11 Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasmaproduct exposed toddlers). Haemophilia 2007; 13 (Suppl. 05) 65-68.
12 Gouw SC, Van der Bom JG, Ljung R. et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-239.
13 Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost 2011; 09: 2180-2192.
14 Hay CR, Palmer B, Chalmers E. et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-6370.
15 Makris M, Calizzani G, Fischer K. et al. EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res 2011; 127 (Suppl. 02) S22-S25.
16 Fischer K, Lewandowski D, Van den Berg HM. et al. Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project. Haemophilia 2012; 18: e241-e246.
17 Wilson EB. Probable influence, the law of succession, and statistical inference. J Am Stat Ass 1927; 22: 209-212.
18 Daly LE. Confidence limits made easy: interval estimation using a substitution method. Am J Epidemiol 1998; 147: 783-790.
19 Eckhardt CL, van Velzen AS, Peters M. et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013; 122: 1954-1962.
20 Mancuso ME, Mannucci PM, Rocino A. et al. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. J Thromb Haemost 2012; 10: 781-790.
21 Kreuz W, Gill JC, Rothschild C. et al. Full-length sucrose-formulated recombinant factorVIII for treatment of previously untreated or minimally treated young children with severe haemophilia A. Thromb Haemost 2005; 93: 457-67.
22 Franchini M, Coppola A, Rocino A. et al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost 2013; 39: 752-766.
23 Iorio A, Matino D, D’Amico R, Makris M. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev 2010; Aug 4 08: CD004449.
24 Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 04: 2576-2581.
25 Puetz J, Soucie JM, Kempton CL. et al. Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database. Haemophilia 2014; 20: 25-31.
26 Soucie JM. Occurrence of haemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998; 59: 188-194.

Zusatzmaterial